CanSino: Inhaled tuberculosis vaccine approved for clinical trials in Indonesia

CanSino announcement: The inhaled lung tuberculosis vaccine developed by the company has recently received clinical trial approval from the Food and Drug Administration of Indonesia. The vaccine aims to enhance the protection of those vaccinated with the BCG vaccine and has completed Phase I and Phase II clinical trials in Canada, demonstrating its safety and efficacy. The inhaled tuberculosis vaccine is delivered through nebulization and is expected to stimulate lung immune responses, clear tuberculosis bacteria, and prevent infection. Currently, there is no enhanced vaccine for tuberculosis prevention globally. This clinical trial will investigate the safety and immunogenicity of a single dose of this vaccine in adults aged 18-49.